Advancing Radiopharmaceuticals for Targeted Cancer Treatment

Combining targeted diagnostics and therapeutic delivery to improve outcomes in oncology.

Innovation & Quality

Pioneering the Future of Nuclear Medicine

Cancer diagnoses can disrupt lives. Juniper Biosciences aims to clarify the path ahead with innovative radiopharmaceuticals. We use radioisotopes and high-specificity ligands to diagnose earlier and treat effectively, reducing side effects and enhancing therapeutic impact.

card-expertise@2x

Expertise

With decades of combined experience in radiopharmaceutical drug development, our team has the expertise and knowledge to reimagine the field and drive our programs forward.

Meet the Experts
card-programs@2x

Programs

We are advancing a pipeline of radiopharmaceutical agents across disease states, balancing proven solutions to transform lives and novel theranostics for a brighter tomorrow.

View Pipeline
card-purpose@2x

Purpose

Our vision is to be a leader in radiopharmaceutical innovation – and that starts with bringing the best and brightest to the family. See how you can help us make a difference.

Join the Team
Pipeline & Programs

Programs Designed to
Transform Patient Outcomes

Balancing clinically proven solutions with novel theranostics across multiple disease states.

Candidate Target Isotope Pre-Clinical Phase I Phase II Phase III Reg. Filing
JBS-003 (F-MISO) HPV+ Head and Neck Cancer Hypoxic Tumor Cells 18F
JBS-005 α Undisclosed Undisclosed Undisc. α-emitter
JBS-005 β Undisclosed Undisclosed Undisc. β-emitter
JBS-005 γ Undisclosed Undisclosed Undisc. PET-emitter
Meet the Team

The Faces Behind Our Science

Alex Agnoletto

Alex Agnoletto

CEO, Co-Founder & Board Member

Dr. Indranil Nandi, PhD

Dr. Indranil Nandi, PhD

COO & Co-Founder

Dr. Kyle Hoffmann, PharmD

Dr. Kyle Hoffmann, PharmD

Director of Manufacturing, Co-Founder

Dr. Serge Lyashchenko, PharmD

Dr. Serge Lyashchenko, PharmD

Advisor, Co-Founder & Board Member

Sharon Roded

Sharon Roded

Advisor, Co-Founder, Board Member

Pietro Bubba Bello

Pietro Bubba Bello

Advisor, Board Member

Yehudah Livneh

Yehudah Livneh

Senior Advisor, Intellectual Property

Sean Campbell

Sean Campbell

General Counsel

Huw Jones

Huw Jones

Senior Advisor, Commercial Strategy

Richard Brodsky

Richard Brodsky

Advisor, Commercial Lead

William Rose

William Rose

Senior Director of Program Management

Chris Marcinek

Chris Marcinek

Controller

Sathya Arunachalam

Sathya Arunachalam

Associate Director of Analytical Development

Dr. Santosh Alluri

Dr. Santosh Alluri

Senior Manager of Pharmaceutical Development

Meysam Bahrami

Meysam Bahrami

Senior Manager of QC

Rinku Soni

Rinku Soni

Associate Director of Program Management

Mike Manley

Mike Manley

Associate Director of Program Management

Javed Mahmood

Javed Mahmood

Senior Director, Clinical Development

What's New

Upsized and Oversubscribed Seed Round Completed at $40 Million

Juniper Biosciences LLC today announced the closing of an oversubscribed and upsized $40 million seed financing through its parent company, Juniper Radiopharma LLC…

Read More
bg-card-news@2x